J&J CEO Says Some Cancers Could Be Cured Within 10 Years
Updated
Updated · Fox News · Jun 17
J&J CEO Says Some Cancers Could Be Cured Within 10 Years
3 articles · Updated · Fox News · Jun 17
Summary
Joaquin Duato said at a London summit that curing certain cancers within the next decade is now a realistic goal, while others could be managed as chronic diseases.
10 years of survival in multiple myeloma, versus only single years before, was Duato’s example of how newer therapies are already extending life and reshaping treatment expectations.
More than five years of remission after a single administration in some end-stage patients shows the promise of immune-based treatments that use a patient’s own system to attack cancer.
AI and biomarkers are expected to speed that shift by improving earlier diagnosis, targeting mutations more precisely and enabling more personalized surgery and treatment.
The broader backdrop is rapid oncology innovation, including positive five-year melanoma data for Merck and Moderna’s personalized mRNA therapy with Keytruda and J&J’s recent Firefly Bio acquisition.
Can we trust AI with life-or-death decisions in the new era of personalized cancer care?
Will breakthrough cancer cures create a new divide between the rich and the poor?
Curing Cancer by 2036? Johnson & Johnson’s Bold Vision, Breakthroughs, and the Challenge of Global Access
Overview
On June 17, 2026, Johnson & Johnson (J&J) CEO Joaquin Duato announced a bold vision at the London CEO summit: to cure certain cancers within a decade and become the world’s leading oncology company by 2030. This ambitious goal sets a new benchmark for the pharmaceutical industry and highlights J&J’s intensified focus on cancer. The company is backing this vision with strategic acquisitions and substantial financial investments, driving broad momentum in its oncology business. These efforts demonstrate J&J’s commitment to transforming cancer care and leading innovation in the fight against this disease.